stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.6%
- Free cash flow
- +20.4%
- Total debt
- +22.1%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) Shares outstanding
Haemonetics Corporation's shares outstanding at the end of fiscal 2026 was $47.4M, down 6.65% from $50.7M in fiscal 2025. At the end of the quarter to 30 September 2026 it was $46.5M. Over the past ten years it has ranged from $47.4M (fiscal 2026) to $53.5M (fiscal 2018) — the current reading is the lowest in ten years. Haemonetics Corporation ranks 63rd of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2026 | $47.4M | (6.65%) |
| FY2025 | $50.7M | (1.30%) |
| FY2024 | $51.4M | (0.04%) |
| FY2023 | $51.4M | 0.13% |
| FY2022 | $51.4M | 0.12% |
| FY2021 | $51.3M | (1.01%) |
| FY2020 | $51.8M | (2.13%) |
| FY2019 | $52.9M | (1.04%) |
| FY2018 | $53.5M | 3.84% |
| FY2017 | $51.5M | 1.21% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $46.5M | 1.66% |
| Jun 2026 | $45.7M | (3.48%) |
| Mar 2026 | $47.4M | 0.78% |
| Dec 2025 | $47.0M | (1.42%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| BRKR Bruker Corporation compare | $152.5M |
| TXG 10x Genomics compare | $130.0M |
| AXGN AxoGen, Inc. compare | $61.5M |
| LIVN LivaNova PLC compare | $57.4M |
| HAE Haemonetics Corporation | $46.5M |
| ITGR Integer Holdings Corporation compare | $34.6M |
| IRTC iRhythm Holdings, Inc. compare | $33.1M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $26.9M |
| BIO Bio-Rad Laboratories, Inc. compare | $26.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on HAE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement